RxDoctor Payments Data

Brian McCool, MD

Otolaryngology · Homewood, ALNPI 1730154972

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,953 of the $2,753 with a category attached, or 70.9%. 20 manufacturers reported payments, led by Optinose US, Inc. at 45.1% of the total. Reporting peaked in 2020 at $1,110 and has fallen 71.9% since, to $311 in 2025.

$2,753in general payments, 2019–2025

Across 89 payments — averaging $30.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$1K
  • Intersect ENT, Inc.$370
  • GSK$191
  • Sanofi$185
  • Medtronic$110
  • Regeneron Healthcare Solutions, Inc.$110
  • plus $546 from 14 others

What the payments were for

  • Consulting fees$80029%
  • Food & beverage$1,95371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,753 in reported general payments places this provider in the 65th percentile of 155 otolaryngology providers in Alabama.

See all otolaryngology providers in Alabama

Medicare billing

Part B allowed, 2024
$50,613
Medicare patients
251
Services billed
948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide50$1,918
Montelukast Sodium36$197

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Homewood

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →